Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
Neurocrine Bio. (NBIX) PT Raised to $100 at Baird After Another Beat for Ingrezza
May 1, 2018 7:15 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $84.00) while maintaining an Outperform rating following another strong quarter for Ingrezza.
Analyst Brian Skorney commented, "Investor fears about a quarter of declining sequential growth turned out to be unfounded as... More
